Literature DB >> 15336337

Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.

Edward Michna1, Edgar L Ross, Wilfred L Hynes, Srdjan S Nedeljkovic, Sharonah Soumekh, David Janfaza, Diane Palombi, Robert N Jamison.   

Abstract

Physicians can encounter problems in prescribing opioids for some patients with chronic pain such as multiple unsanctioned dose escalations, episodes of lost or stolen prescriptions, and positive urine drug screenings for illicit substances. This study explored the usefulness of questions on abuse history in predicting problems with prescribing opioids for patients at a hospital-based pain management program. One hundred forty-five (145) patients who were taking long- and short-acting opioids for their pain were classified as high or low risk on the basis of their responses to interview questions about 1) substance abuse history in their family, 2) past problems with drug or alcohol abuse, and 3) history of legal problems. The treating physicians completed a questionnaire about problems that they had encountered with their patients. Problem behaviors were verified through chart review. No differences in demographic characteristics were found between those classified as high and low risk. Patients who admitted to a family history of substance abuse, a history of legal problems, and drug or alcohol abuse were prone to more aberrant drug-related behaviors, including a higher incidence of lost or stolen prescriptions and the presence of illicit substances in their urine (P < 0.05). Patients classified as high risk also had a significantly higher frequency of reported mental health problems and motor vehicle accidents. More of these patients smoked cigarettes, tended to need a cigarette within the first hour of the day, took higher doses of opioids, and reported fewer adverse effects from the medications than did those without such a history (P < 0.05). This study demonstrates that questions about abuse history and legal problems can be useful in predicting aberrant drug-related behavior with opioid use in persons with chronic noncancer pain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336337     DOI: 10.1016/j.jpainsymman.2004.04.007

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  120 in total

1.  Pain Status as a Predictor of Smoking Cessation Initiation, Lapse, and Relapse.

Authors:  Joseph W Ditre; Bryan W Heckman; Lisa R LaRowe; Jessica M Powers
Journal:  Nicotine Tob Res       Date:  2021-01-07       Impact factor: 4.244

2.  Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

3.  S-ketamine concentrations are greatly increased by grapefruit juice.

Authors:  Marko A Peltoniemi; Teijo I Saari; Nora M Hagelberg; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

4.  Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors.

Authors:  Kathleen W Saunders; Michael Von Korff; Cynthia I Campbell; Caleb J Banta-Green; Mark D Sullivan; Joseph O Merrill; Constance Weisner
Journal:  J Pain       Date:  2012-01-29       Impact factor: 5.820

5.  Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial.

Authors:  Robert N Jamison; Edgar L Ross; Edward Michna; Li Q Chen; Caroline Holcomb; Ajay D Wasan
Journal:  Pain       Date:  2010-03-23       Impact factor: 6.961

6.  Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.

Authors:  Jane M Liebschutz; Richard Saitz; Roger D Weiss; Tali Averbuch; Sonia Schwartz; Ellen C Meltzer; Elizabeth Claggett-Borne; Howard Cabral; Jeffrey H Samet
Journal:  J Pain       Date:  2010-03-24       Impact factor: 5.820

Review 7.  [Risk factors for substance abuse and dependence in opioid therapy for chronic noncancer-related pain].

Authors:  J Jage; A Willweber-Strumpf; C Maier
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

8.  Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.

Authors:  Nora M Hagelberg; Tuukka Saarikoski; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Miia Turpeinen; Mika Scheinin; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-10-26       Impact factor: 2.953

9.  Primary care providers' views on chronic pain management among high-risk patients in safety net settings.

Authors:  Maya Vijayaraghavan; Joanne Penko; David Guzman; Christine Miaskowski; Margot B Kushel
Journal:  Pain Med       Date:  2012-07-30       Impact factor: 3.750

10.  Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).

Authors:  Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison
Journal:  J Pain       Date:  2008-01-22       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.